Acessibilidade / Reportar erro

Brazilian dental consensus on dental management in hematopoietic stem cell transplantation−Part I−pre-HSCT

ABSTRACT

The oral involvement in the Hematopoietic Stem Cell Transplantation is well described in the literature. The goal of the dental treatment and management of the oral lesions related to the HSCT is to reduce the harm caused by preexisting oral infection or even the worsening of oral acute/chronic GVHD and late effects. The aim of this guideline was to discuss the dental management of patients subjected to HSCT, considering three phases of the HSCT: pre-HSCT, acute phase, and late phase. The literature published from 2010 to 2020 was reviewed in order to identify dental interventions in this patient population. The selected papers were divided into three groups: pre-HSCT, acute and late, and were reviewed by the SBTMO Dental Committee's members. When necessary, an expertise opinion was considered for better translating the guideline recommendations to our population dental characteristics. This manuscript focused on the pre-HSCT dental management. The objective of the pre-HSCT dental management is to identify possible dental situations that On behalf of the Dental Committee of the Brazilian Society of Gene Therapy and Bone Marrow Transplantation (SBTMO) can worsening during the acute phase after the HSCT. Each guideline recommendations were made considering the Dentistry Specialties. The clinical consensus on dental management prior to HSCT provides professional health caregivers with clinical setting-specific information to help with the management of dental problems in patients to be subjected to HSCT.

Keywords:
Hematopoietic stem cell transplantation; Dental management; Consensus; Dentistry; Brazilian guideline

Introduction

HSCT-related oral complications is recognized in the literature and is estimated to be present in about 80% of patients undergoing this therapeutic modality.11 Angelo SN, Yamaguti GG, Lourenco GJ, Honma HN, Silva EF, Sagarra AF, et al. The role of the CYP1A1 gene defects in cancer risk in southeastern Brazil. J Clin Oncol. 2008;26(15).,22 Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62(6):400–22.,33 Epstein JB, Raber-Durlacher JE, Raber-Drulacher JE, Wilkins A, Chavarria MG, Myint H. Advances in hematologic stem cell transplant: an update for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(3):301–12.,44 Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98(7):1531–9. These oral complications can directly impact complications and the patient's quality of life during HSCT 44 Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98(7):1531–9.,55 Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23(1):223–36.,66 Mank A, Quinn B, Wallhult E, Raber-Durlacher J, Elad S, Brennan MT, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50:S501.. -S.,77 Boer CC, Correa MEP, Tenuta LMA, Souza CA, Vigorito AC. Post-allogeneic Hematopoietic Stem Cell Transplantation (HSCT) changes in inorganic salivary components. Support Care Cancer. 2015;23(9):2561–7.,88 Alborghetti MR, Correa MEP, Adam RL, Metze K, Coracin FL, de Souza CA, et al. Late effects of chronic graft-vs.-host disease in minor salivary glands. J Oral Pathol Med. 2005;34(8):486–93.,99 Noce CW, Gomes A, Copello A, Barbosa RD, Sant'anna S, Moreira MC, et al. Oral involvement of chronic graft-versus-host disease in hematopoietic stem cell transplant recipients. Gen Dent. 2011;59(6):458–62. quiz 63-4.

The management of the oral cavity in patients undergoing HSCT is of utmost importance.55 Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23(1):223–36.,1010 Samim F, Ten Böhmer KL, Koppelmans RGA, Raber-Durlacher JE, Epstein JB. Oral care for hematopoietic stem cell transplantation patients: a narrative review. Oral Health Prev Dent. 2019;17(5):413–23. This management can be subdivided into three stages; pre-HSCT; during HSCT, and late phase of HSCT.55 Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23(1):223–36. Each phase has specific characteristics in terms of oral complications and oral management. Thus, the importance of pre-existing oral infections in the pre-HSCT phase, the oral assessment during oral complications in the initial phase, and the diagnosis and management of chronic oral oral/dental complications in the late phase have been discussed.55 Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23(1):223–36.,1010 Samim F, Ten Böhmer KL, Koppelmans RGA, Raber-Durlacher JE, Epstein JB. Oral care for hematopoietic stem cell transplantation patients: a narrative review. Oral Health Prev Dent. 2019;17(5):413–23.

In the light of the reports, a group of oral medicine experts was invited by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) to develop a guideline for HSCT patients' dental care, taking into consideration the oral health characteristics of the Brazilian population.

Therefore, this is the first in a series of 3 articles that will discuss the dental management of the HSCT population. These manuscripts intend to provide continuing education to fellow dental surgeons on this specific area of care and, consequently, to facilitate HSCT patient's access to dental care.

Objective

The aim of this positioning manuscript was to provide recommendations by the Dental Committee of the Brazilian Society of Bone Cell Transplantation (SBTMO) for basic oral healthcare and dental treatment for patients undergoing the HSCT.

This article intends to detail the specific management guideline of various dental conditions that should be considered before the HSCT.

Review methods

A narrative review was conducted on the database MEDLINE/ PubMed and Embase. The primary outcome was to retrieve original data on relevant articles containing dental protocols in patients undergoing the HSCT. All original studies in English, Spanish or Portuguese assessing oral health, oral complications and dental procedures in adult and pediatric patients subjected to HSCT were reviewed by the group of oral medicine experts. Manuscripts written in different languages other than the ones mentioned above, conference abstracts, case reports, and articles including solid tumors were excluded.

The panel of experts reviewed the selected articles and then discussed the most important aspects involving oral health through virtual meetings. Thus, the recommendations in these 3 steps guide was obtained based on literature data and on the experts' clinical experience.

The articles and the experts were divided into three groups:l. Oral care before HSCT (oral preparation for HSCT); 2. Oral care during HSCT (until neutrophil engraftment) and 3. Special topics on oral health.

For this first article, the search strategy combined all key terms for HSCT, including the key terms separately or in combination: management, dental, oral, tooth, procedures, prophylaxis and surgery, health, Brazil, infection, submucosal scaling, periodontal and dentoalveolar surgery, endodontic, restorative, and orthodontic treatment published from the period of January 2010 to December of 2020 (Figure 1).

Figure 1
Flowchart of the study.

Review/results

General consideration

The objective of pre-HSCT dental management is to minimize risks of dental origin infections that may increase the patient's morbidity, during the first 100 days of HSCT.1111 Mendes SR, Silva MES, Firmo JOA, de Abreu MHNG. What haematopoietic stem cell transplant patients think about health and oral care: a qualitative study in a Brazilian health service. Eur J Cancer Care. 2018;27(3):e12851.,1212 Santos PS, Coracin FL, Barros JC, Dulley FL, Nunes FD, Magalhães MG. Impact of oral care prior to HSCT on the severity and clinical outcomes of oral mucositis. Clin Transplant. 2011;25(2):325–8.,1313 Seppänen L, Lemberg KK, Lauhio A, Lindqvist C, Rautemaa R. Is dental treatment of an infected tooth a risk factor for locally invasive spread of infection? J Oral Maxillofac Surg. 2011;69 (4):986–93. It is important to establish good communication between the transplant team and the dental group for the patient's best care. Dental treatment planning requires that the dentist (oral medicine) understands the basic principles of the diseases that lead to HSCT and the different treatment protocols involved in patient's care (Figures 2 and 3).55 Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23(1):223–36.

Figure 2
Flowchart for initial dental appointment.

Figure 3
Flowchart for proposing a dental treatment plan before HSCT. Abbreviations: ATB- antibiotic.

Ideally, an initial dental appointment should be scheduled as sooner as possible to allow sufficient time for the dental treatment needed and to give time for tissues to heal after surgical procedure, preferably with a healing period of 2 to 3 weeks after the completion of the dental treatment (Figure 2).55 Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23(1):223–36.,1414 Hansen HJ, Estilo C, Owosho A, Solano AK, Randazzo J, Huryn J, et al. Dental status and risk of odontogenic complication in patients undergoing hematopoietic stem cell transplant. Support Care Cancer. 2021;29(4):2231–8. Previous dental assessment is indispensable regardless the time available for transplantation.

In mouth preparation, the resolution of infection foci must be prioritized. The indication of a surgical procedure out of the ideal time for healing should be discussed according to each case. Nevertheless, time constraints and patients medical condition may require modification of the dental treatment plan (Figure 3).55 Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23(1):223–36.,1515 Durey K, Patterson H, Gordon K. Dental assessment prior to stem cell transplant: treatment need and barriers to care. Br Dent J. 2009;206(9):E19.. discussion 478-9.,1616 Elad S, Garfunkel AA, Or R, Michaeli E, Shapira MY, Galili D. Time limitations and the challenge of providing infection-preventing dental care to hematopoietic stem-cell transplantation patients. Support Care Cancer. 2003;11(10):674–7.

Elective additional dental needs identified in pre-HSCT examination should be postponed to when the patient's overall health status allows it.55 Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23(1):223–36.

Special considerations

Laboratory tests, such as blood count and platelets count, should be performed before dental treatment, mostly if the patient was underdoing any treatment that could increase the risk of bleeding or the risk of systemic and/or local infection. Other blood exam such coagulation screening should be performed in those patients which may present coagulation disorders.1717 Hupp WS, Firriolo FJ, De Rossi SS. Laboratory evaluation of chronic medical conditions for dental treatment: Part III. Hematology. Compend Contin Educ Dent. 2011;32(7). 10-2, 4-8; quiz 20, 32.

Antibiotic prophylaxis (AP), antibiotic treatment (AT), and the dental treatment plan need to be carefully discussed between the medical, dental, and multidisciplinary team before the dental treatment. The discussion should consider the underlying disease status, the current patient's immune status, and the risk of the dental procedure for local or systemic infection.1313 Seppänen L, Lemberg KK, Lauhio A, Lindqvist C, Rautemaa R. Is dental treatment of an infected tooth a risk factor for locally invasive spread of infection? J Oral Maxillofac Surg. 2011;69 (4):986–93.,1717 Hupp WS, Firriolo FJ, De Rossi SS. Laboratory evaluation of chronic medical conditions for dental treatment: Part III. Hematology. Compend Contin Educ Dent. 2011;32(7). 10-2, 4-8; quiz 20, 32.,1818 Morimoto Y, Niwa H, Imai Y, Kirita T. Dental management prior to hematopoietic stem cell transplantation. Spec Care Dentist. 2004;24(6):287–92. (Table 1)

Table 1
Oral pre-HSCT conditions, classification of risk of local and systemic complications due to previous dental conditions and Dental Treatment recommendation.

Dental management

1 – Basic oral care

The maintenance of oral hygiene, through tooth brushing, must be reinforced and maintained throughout the HSCT period. It has been reported the beneficial effect of Chlorhexidine mouthwash use in association with tooth brushing on the reduction of gingival inflammation.1919 James P, Worthington HV, Parnell C, Harding M, Lamont T, Cheung A, et al. Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database Syst Rev. 2017;3:CD008676.,2020 Van der Weijden FA, Van der Sluijs E, Ciancio SG, Slot DE. Can chemical mouthwash agents achieve plaque/gingivitis control? Dent Clin North Am. 2015;59(4):799–829. Therefore, Chlorhexidine mouth wash should be recommended as an auxiliar therapy in periodontal treatment.2020 Van der Weijden FA, Van der Sluijs E, Ciancio SG, Slot DE. Can chemical mouthwash agents achieve plaque/gingivitis control? Dent Clin North Am. 2015;59(4):799–829.,2121 Nashwan AJ. Use of Chlorhexidine mouthwash in children receiving chemotherapy: a review of literature. J Pediatr Oncol Nurs. 2011;28(5):295–9. Chlorhexidine can also be recommended for biofilm control for those patients who present exposed necrotic bone.1919 James P, Worthington HV, Parnell C, Harding M, Lamont T, Cheung A, et al. Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database Syst Rev. 2017;3:CD008676.,2222 Teshome A. The efficacy of Chlorhexidine gel in the prevention of alveolar osteitis after mandibular third molar extraction: a systematic review and meta-analysis. BMC Oral Health. 2017;17(1):82.

The anticariogenic benefits of fluoride therapy is well documented in the literature.2323 Weyant RJ, Tracy SL, Anselmo TT, Beltrán-Aguilar ED, Donly KJ, Frese WA, et al. Topical fluoride for caries prevention: executive summary of the updated clinical recommendations and supporting systematic review. J Am Dent Assoc. 2013;144 (11):1279–91. Compromised oral health, high caries risk, alteration of caries-related factors, and dysbiosis of oral microbiota were related to cancer treatment in children2424 Wang Y, Zeng X, Yang X, Que J, Du Q, Zhang Q, et al. Oral Health, Caries Risk Profiles, and Oral Microbiome of Pediatric Patients with Leukemia Submitted to Chemotherapy. Biomed Res Int. 2021;2021:6637503. and in patients who underwent HSCT.2525 Saleh W, Katz J. Periodontal diseases, caries, and dental abscesses prevalence in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021;56(3):720–2.,2626 Santos-Silva AR, PoS Feio, Vargas PA, Correa ME, Lopes MA. cGVHD-related caries and its shared features with other 'dry-mouth'-related caries. Braz Dent J. 2015;26(4):435–40.,2727 Castellarin P, Stevenson K, Biasotto M, Yuan A, Woo SB, Treister NS. Extensive dental caries in patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012;18(10):1573–9. These findings may be critical to the development of strategies for personalized preventive management of dental caries for this patient population.2424 Wang Y, Zeng X, Yang X, Que J, Du Q, Zhang Q, et al. Oral Health, Caries Risk Profiles, and Oral Microbiome of Pediatric Patients with Leukemia Submitted to Chemotherapy. Biomed Res Int. 2021;2021:6637503.

2 – Dental assessment

2.1 – Periodontal treatment – the presence of periodontal disease has been considered a risk condition for local and systemic infection and local bleeding complications in the first 100 days of HSCT.2828 Wu Y, Shi X, Li Y, Gu Y, Qian Q, Hong Y. Hematopoietic and lymphatic cancers in patients with periodontitis: a systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020;25(1):e21–e8.,2929 Raber-Durlacher JE, Laheij AM, Epstein JB, Epstein M, Geerligs GM, Wolffe GN, et al. Periodontal status and bacteremia with oral viridans streptococci and coagulase negative staphylococci in allogeneic hematopoietic stem cell transplantation recipients: a prospective observational study. Support Care Cancer. 2013;21(6):1621–7.,3030 Hong CHL, Hu S, Haverman T, Stokman M, Napeñas JJ, Braber JB, et al. A systematic review of dental disease management in cancer patients. Support Care Cancer. 2018;26(l):155–74.,3131 Gürgan CA, Özcan M, Karakuş Ö, Zincircioğlu G, Arat M, Soydan E, et al. Periodontal status and post-transplantation complications following intensive periodontal treatment in patients underwent allogenic hematopoietic stem cell transplantation conditioned with myeloablative regimen. Int J Dent Hyg. 2013;11(2):84–90. It is important to establish a routine periodontal screening in order to facilitate the treatment planning as well as the periodontal follow-up in this patient population.2929 Raber-Durlacher JE, Laheij AM, Epstein JB, Epstein M, Geerligs GM, Wolffe GN, et al. Periodontal status and bacteremia with oral viridans streptococci and coagulase negative staphylococci in allogeneic hematopoietic stem cell transplantation recipients: a prospective observational study. Support Care Cancer. 2013;21(6):1621–7. In this article, Periodontal Screening & Recording (PSR)3232 Landry RG, Jean M. Periodontal Screening and Recording (PSR) Index: precursors, utility and limitations in a clinical setting. Int Dent J. 2002;52(1):35–40. was used as a guidance method for comprehensive periodontal assessment. The recommendations for periodontal management based on the PSR criteria, the risk for local or systemic complication of the previous periodontal condition to the initial phase of the HSCT, and the timing for its execution and tissue healing were detailed in Table 1.

2.2 – Caries treatment –restorative treatment usually does not represent a risk of complication for these patients. Extensive dental caries with potential endodontic involvement can represent a risk for pulpitis and infection.1313 Seppänen L, Lemberg KK, Lauhio A, Lindqvist C, Rautemaa R. Is dental treatment of an infected tooth a risk factor for locally invasive spread of infection? J Oral Maxillofac Surg. 2011;69 (4):986–93.,3333 Bordagaray MJ, Fernández A, Garrido M, Astorga J, Hoare A, Hernández M. Systemic and extraradicular bacterial translocation in apical periodontitis. Front Cell Infect Microbiol. 2021;11:649925. Some dental conditions, such sharper broken dental crown, can represent risk for mucosal injury mostly during the mucositis period. These situations should be managed before the HSCT (Table 1).

2.3 – Exodontia – dental extraction represents risk of local/ systemic infection and bleeding. As well as in all invasive dental treatment, special concern about the risk of infection and bleeding must be part of the dental assessment plan and must be discussed with the medical team. Proper attention should be devoted to those patients who present risk of developing osteonecrosis of the jaw regarding the use of antibiotics prophylaxis.3434 Igoumenakis D, Giannakopoulos NN, Parara E, Mourouzis C, Rallis G Effect of causative tooth extraction on clinical and biological parameters of odontogenic infection: a prospective clinical trial. J Oral Maxillofac Surg. 2015;73(7):1254–8.,3535 Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019;27(2):383–94.,3636 Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(2):117–35. Other clinical situations, such as residual root, which require invasive approaches are detailed in Table 1.

2.4 – Third Molar – third molar extraction can present a high incidence of complications3737 Ohman D, Björk Y, Bratel J, Kristiansson C, Johansson P, Johansson JE, et al. Partially erupted third molars as a potential source of infection in patients receiving peripheral stem cell transplantation for malignant diseases: a retrospective study. Eur J Oral Sci. 2010;118(1):53–8. that might impair the HSCT schedule. In this guideline, third molar extraction was recommended for symptomatic non-erupted and semierupted third molar or for those patients at high risk of developing chronic GVHD. It is mandatory to consider the timing for complete wound healing before the HSCT conditioning regimen initiation. If there is not available healing time, consider non-invasive management. (Table 1)

2.5 – Endodontic treatment – due to the different endodontic treatment needs and the uncertainty of the time required for apical sterilization, there is a discussion on the literature focusing on the risk of acute infection reactivation during the immunosuppression period of HSCT.1313 Seppänen L, Lemberg KK, Lauhio A, Lindqvist C, Rautemaa R. Is dental treatment of an infected tooth a risk factor for locally invasive spread of infection? J Oral Maxillofac Surg. 2011;69 (4):986–93.,3333 Bordagaray MJ, Fernández A, Garrido M, Astorga J, Hoare A, Hernández M. Systemic and extraradicular bacterial translocation in apical periodontitis. Front Cell Infect Microbiol. 2021;11:649925. In this guideline, the recommendation for endodontic treatment took into consideration the presence of signs or symptoms of infection and, within the required timeframe for the HSCT initiation. (Table 1)

2.6 – Orthodontic appliance – orthodontic appliances can impair the oral basic care and raise the risk of mucosal harm, mostly during the oral mucositis period.3838 Marothiya S, Jain U, Bharti C, Polke P, Agrawal P, Shah R, et al. Evaluation of changes in microbiology and periodontal parameters during and after fixed orthodontic appliances. Mymensingh Med J. 2020;29(4):983–90. In this guideline, the recommendation is to avoid the use of removable appliances and withdraw the fixed orthodontic apparatus before the initiation of the conditioning regimen up to day 100 of the HSCT (Table 1).

2.7 – Children Patients – for the pediatric HSCT population, the dental planning should take into consideration the same rationale described above in terms of basic oral care, good relationship between the medical and dental team, and dental management strategies. However, the recommendation for oral hygiene, including toothbrushing technique and mouthwash, should be personalized based on the children age and the motor coordination.3939 Gibson F, Auld EM, Bryan G, Coulson S, Craig JV, Glenny AM. A systematic review of oral assessment instruments: what can we recommend to practitioners in children's and young people's cancer care? Cancer Nurs. 2010;33(4): E1–E19.,4040 Glenny AM, Gibson F, Auld E, Coulson S, Clarkson JE, Craig JV, et al. The development of evidence-based guidelines on mouth care for children, teenagers and young adults treated for cancer. Eur J Cancer. 2010;46(8):1399–412.,4141 Marinho VC, LY Chong, Worthington HV, Walsh T. Fluoride mouthrinses for preventing dental caries in children and adolescents. Cochrane Database Syst Rev. 2016;7:CD002284.,4242 Hong CH, daFonseca M. Considerations in the pediatric population with cancer. Dent Clin North Am. 2008;52(1):155–81. ix.,4343 Yamagata K, Onizawa K, Yoshida H, Kojima Y, Koike K, Tsuchida M. Dental management of pediatric patients undergoing hematopoietic stem cell transplant. Pediatr Hematol Oncol. 2006;23(7):541–8. The dental approach for deciduous teeth must consider the degree of the deciduous root resorption and the degree of the permanent root growth (Tablel).4040 Glenny AM, Gibson F, Auld E, Coulson S, Clarkson JE, Craig JV, et al. The development of evidence-based guidelines on mouth care for children, teenagers and young adults treated for cancer. Eur J Cancer. 2010;46(8):1399–412.

Discussion and conclusion

The development of a guideline of dental care addressed to patients to be subjected to HSCT, aligned with the population characteristics of oral health in our country, provides tools to general dentists and oral medicine professionals in providing a safe dental treatment to this particular group of patients.

The last oral health survey conducted by the Brazilian Ministry of Health4444 Ministério da Saúde B. Pesquisa Nacional de Saúde Bucal: resultados principais. SB Brasil: Secretaria de Vigilância em Saúde; 2012. showed that periodontal disease, as well as dental caries, are the oral infections of the highest prevalence and incidence in our population. These findings have been observed since childhood and are perpetuated into adulthood, probably being responsible for the high incidence of edentulous adults (>60 years) in Brazil.4444 Ministério da Saúde B. Pesquisa Nacional de Saúde Bucal: resultados principais. SB Brasil: Secretaria de Vigilância em Saúde; 2012.

The impact of pre-HSCT dental treatment on the early phase events of HSCT, such as oral mucositis, is not well determined in the literature. However, it is common sense that oral cavity preparation, as well as the removal of infectious foci, should be performed in these patients to decrease the risk of developing local and/or systemic infections of odontogenic origin.55 Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23(1):223–36.,66 Mank A, Quinn B, Wallhult E, Raber-Durlacher J, Elad S, Brennan MT, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50:S501.. -S.

A study carried out in a Brazilian tertiary service found a high incidence of periodontal (33%) and endodontic (15%) foci, and active caries (27%) in pre-transplant patients. In the same study, oral diseases and poor oral health indices were more frequent in children and young people with chronic oncohematologic diseases. About 50% of these patients showed some necessity for dental intervention before HSCT.4545 Reis TC, Bortolotti F, Innocentini LMAR, Ferrari TC, Ricz HMA, Cunha RLG, et al. Assessment of oral health condition in recipients of allogeneic hematopoietic cell transplantation. Hematol Transfus Cell Ther. 2021. These findings have been corroborated by studies published in the literature.1616 Elad S, Garfunkel AA, Or R, Michaeli E, Shapira MY, Galili D. Time limitations and the challenge of providing infection-preventing dental care to hematopoietic stem-cell transplantation patients. Support Care Cancer. 2003;11(10):674–7.,4646 Lucas VS, Roberts GJ, Beighton D. Oral health of children undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998;22(8):801–8.,4747 Yamagata K, Onizawa K, Yanagawa T, Hasegawa Y, Kojima H, Nagasawa T, et al. A prospective study to evaluate a new dental management protocol before hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38 (3):237–42.

In Brazil, not every Bone Marrow Transplant Services have a dentist as a member of the multidisciplinary team. In these situations, patients need to be evaluated by dentists working in public dental services or in private practices, where the professionals may not be familiar with the particularities of dental care for this specific group of patients. This guideline was written taking into consideration the characteristics of oral health described in the Brazilian Oral Health Survey4444 Ministério da Saúde B. Pesquisa Nacional de Saúde Bucal: resultados principais. SB Brasil: Secretaria de Vigilância em Saúde; 2012. and the most frequent dental conditions observed in the clinical routine of the Dentistry services of the Transplant Centers in Brazil.

The details of the procedures described here considered the general health conditions of the patient and the time between the end of the dental treatment and the beginning of the HSCT emphasizing the importance of the close work between the dentist and the multidisciplinary team. We hope to facilitate the patient's access to safe and effective dental treatment.

Acknowledgements

We thank the Brazilian Bone Marrow Transplantation Society (SBTMO) for the support and trusting in our team. We also thank Nathalia Cristine André for her assistance.

  • Funding information
    This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
  • Statement of clinical relevance
    The complications in the oral cavity may increase mortality and morbidity in the different phases of the hematopoietic stem cell transplantation. There is not a Brazilian guideline that guides the work of dentists with patients subjected to HSCT. This first part of the consensus offers guidance towards pre-HSCT dental intervention.

REFERENCES

  • 1
    Angelo SN, Yamaguti GG, Lourenco GJ, Honma HN, Silva EF, Sagarra AF, et al. The role of the CYP1A1 gene defects in cancer risk in southeastern Brazil. J Clin Oncol. 2008;26(15).
  • 2
    Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62(6):400–22.
  • 3
    Epstein JB, Raber-Durlacher JE, Raber-Drulacher JE, Wilkins A, Chavarria MG, Myint H. Advances in hematologic stem cell transplant: an update for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(3):301–12.
  • 4
    Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98(7):1531–9.
  • 5
    Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23(1):223–36.
  • 6
    Mank A, Quinn B, Wallhult E, Raber-Durlacher J, Elad S, Brennan MT, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50:S501.. -S.
  • 7
    Boer CC, Correa MEP, Tenuta LMA, Souza CA, Vigorito AC. Post-allogeneic Hematopoietic Stem Cell Transplantation (HSCT) changes in inorganic salivary components. Support Care Cancer. 2015;23(9):2561–7.
  • 8
    Alborghetti MR, Correa MEP, Adam RL, Metze K, Coracin FL, de Souza CA, et al. Late effects of chronic graft-vs.-host disease in minor salivary glands. J Oral Pathol Med. 2005;34(8):486–93.
  • 9
    Noce CW, Gomes A, Copello A, Barbosa RD, Sant'anna S, Moreira MC, et al. Oral involvement of chronic graft-versus-host disease in hematopoietic stem cell transplant recipients. Gen Dent. 2011;59(6):458–62. quiz 63-4.
  • 10
    Samim F, Ten Böhmer KL, Koppelmans RGA, Raber-Durlacher JE, Epstein JB. Oral care for hematopoietic stem cell transplantation patients: a narrative review. Oral Health Prev Dent. 2019;17(5):413–23.
  • 11
    Mendes SR, Silva MES, Firmo JOA, de Abreu MHNG. What haematopoietic stem cell transplant patients think about health and oral care: a qualitative study in a Brazilian health service. Eur J Cancer Care. 2018;27(3):e12851.
  • 12
    Santos PS, Coracin FL, Barros JC, Dulley FL, Nunes FD, Magalhães MG. Impact of oral care prior to HSCT on the severity and clinical outcomes of oral mucositis. Clin Transplant. 2011;25(2):325–8.
  • 13
    Seppänen L, Lemberg KK, Lauhio A, Lindqvist C, Rautemaa R. Is dental treatment of an infected tooth a risk factor for locally invasive spread of infection? J Oral Maxillofac Surg. 2011;69 (4):986–93.
  • 14
    Hansen HJ, Estilo C, Owosho A, Solano AK, Randazzo J, Huryn J, et al. Dental status and risk of odontogenic complication in patients undergoing hematopoietic stem cell transplant. Support Care Cancer. 2021;29(4):2231–8.
  • 15
    Durey K, Patterson H, Gordon K. Dental assessment prior to stem cell transplant: treatment need and barriers to care. Br Dent J. 2009;206(9):E19.. discussion 478-9.
  • 16
    Elad S, Garfunkel AA, Or R, Michaeli E, Shapira MY, Galili D. Time limitations and the challenge of providing infection-preventing dental care to hematopoietic stem-cell transplantation patients. Support Care Cancer. 2003;11(10):674–7.
  • 17
    Hupp WS, Firriolo FJ, De Rossi SS. Laboratory evaluation of chronic medical conditions for dental treatment: Part III. Hematology. Compend Contin Educ Dent. 2011;32(7). 10-2, 4-8; quiz 20, 32.
  • 18
    Morimoto Y, Niwa H, Imai Y, Kirita T. Dental management prior to hematopoietic stem cell transplantation. Spec Care Dentist. 2004;24(6):287–92.
  • 19
    James P, Worthington HV, Parnell C, Harding M, Lamont T, Cheung A, et al. Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database Syst Rev. 2017;3:CD008676.
  • 20
    Van der Weijden FA, Van der Sluijs E, Ciancio SG, Slot DE. Can chemical mouthwash agents achieve plaque/gingivitis control? Dent Clin North Am. 2015;59(4):799–829.
  • 21
    Nashwan AJ. Use of Chlorhexidine mouthwash in children receiving chemotherapy: a review of literature. J Pediatr Oncol Nurs. 2011;28(5):295–9.
  • 22
    Teshome A. The efficacy of Chlorhexidine gel in the prevention of alveolar osteitis after mandibular third molar extraction: a systematic review and meta-analysis. BMC Oral Health. 2017;17(1):82.
  • 23
    Weyant RJ, Tracy SL, Anselmo TT, Beltrán-Aguilar ED, Donly KJ, Frese WA, et al. Topical fluoride for caries prevention: executive summary of the updated clinical recommendations and supporting systematic review. J Am Dent Assoc. 2013;144 (11):1279–91.
  • 24
    Wang Y, Zeng X, Yang X, Que J, Du Q, Zhang Q, et al. Oral Health, Caries Risk Profiles, and Oral Microbiome of Pediatric Patients with Leukemia Submitted to Chemotherapy. Biomed Res Int. 2021;2021:6637503.
  • 25
    Saleh W, Katz J. Periodontal diseases, caries, and dental abscesses prevalence in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021;56(3):720–2.
  • 26
    Santos-Silva AR, PoS Feio, Vargas PA, Correa ME, Lopes MA. cGVHD-related caries and its shared features with other 'dry-mouth'-related caries. Braz Dent J. 2015;26(4):435–40.
  • 27
    Castellarin P, Stevenson K, Biasotto M, Yuan A, Woo SB, Treister NS. Extensive dental caries in patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012;18(10):1573–9.
  • 28
    Wu Y, Shi X, Li Y, Gu Y, Qian Q, Hong Y. Hematopoietic and lymphatic cancers in patients with periodontitis: a systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020;25(1):e21–e8.
  • 29
    Raber-Durlacher JE, Laheij AM, Epstein JB, Epstein M, Geerligs GM, Wolffe GN, et al. Periodontal status and bacteremia with oral viridans streptococci and coagulase negative staphylococci in allogeneic hematopoietic stem cell transplantation recipients: a prospective observational study. Support Care Cancer. 2013;21(6):1621–7.
  • 30
    Hong CHL, Hu S, Haverman T, Stokman M, Napeñas JJ, Braber JB, et al. A systematic review of dental disease management in cancer patients. Support Care Cancer. 2018;26(l):155–74.
  • 31
    Gürgan CA, Özcan M, Karakuş Ö, Zincircioğlu G, Arat M, Soydan E, et al. Periodontal status and post-transplantation complications following intensive periodontal treatment in patients underwent allogenic hematopoietic stem cell transplantation conditioned with myeloablative regimen. Int J Dent Hyg. 2013;11(2):84–90.
  • 32
    Landry RG, Jean M. Periodontal Screening and Recording (PSR) Index: precursors, utility and limitations in a clinical setting. Int Dent J. 2002;52(1):35–40.
  • 33
    Bordagaray MJ, Fernández A, Garrido M, Astorga J, Hoare A, Hernández M. Systemic and extraradicular bacterial translocation in apical periodontitis. Front Cell Infect Microbiol. 2021;11:649925.
  • 34
    Igoumenakis D, Giannakopoulos NN, Parara E, Mourouzis C, Rallis G Effect of causative tooth extraction on clinical and biological parameters of odontogenic infection: a prospective clinical trial. J Oral Maxillofac Surg. 2015;73(7):1254–8.
  • 35
    Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019;27(2):383–94.
  • 36
    Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(2):117–35.
  • 37
    Ohman D, Björk Y, Bratel J, Kristiansson C, Johansson P, Johansson JE, et al. Partially erupted third molars as a potential source of infection in patients receiving peripheral stem cell transplantation for malignant diseases: a retrospective study. Eur J Oral Sci. 2010;118(1):53–8.
  • 38
    Marothiya S, Jain U, Bharti C, Polke P, Agrawal P, Shah R, et al. Evaluation of changes in microbiology and periodontal parameters during and after fixed orthodontic appliances. Mymensingh Med J. 2020;29(4):983–90.
  • 39
    Gibson F, Auld EM, Bryan G, Coulson S, Craig JV, Glenny AM. A systematic review of oral assessment instruments: what can we recommend to practitioners in children's and young people's cancer care? Cancer Nurs. 2010;33(4): E1–E19.
  • 40
    Glenny AM, Gibson F, Auld E, Coulson S, Clarkson JE, Craig JV, et al. The development of evidence-based guidelines on mouth care for children, teenagers and young adults treated for cancer. Eur J Cancer. 2010;46(8):1399–412.
  • 41
    Marinho VC, LY Chong, Worthington HV, Walsh T. Fluoride mouthrinses for preventing dental caries in children and adolescents. Cochrane Database Syst Rev. 2016;7:CD002284.
  • 42
    Hong CH, daFonseca M. Considerations in the pediatric population with cancer. Dent Clin North Am. 2008;52(1):155–81. ix.
  • 43
    Yamagata K, Onizawa K, Yoshida H, Kojima Y, Koike K, Tsuchida M. Dental management of pediatric patients undergoing hematopoietic stem cell transplant. Pediatr Hematol Oncol. 2006;23(7):541–8.
  • 44
    Ministério da Saúde B. Pesquisa Nacional de Saúde Bucal: resultados principais. SB Brasil: Secretaria de Vigilância em Saúde; 2012.
  • 45
    Reis TC, Bortolotti F, Innocentini LMAR, Ferrari TC, Ricz HMA, Cunha RLG, et al. Assessment of oral health condition in recipients of allogeneic hematopoietic cell transplantation. Hematol Transfus Cell Ther. 2021.
  • 46
    Lucas VS, Roberts GJ, Beighton D. Oral health of children undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998;22(8):801–8.
  • 47
    Yamagata K, Onizawa K, Yanagawa T, Hasegawa Y, Kojima H, Nagasawa T, et al. A prospective study to evaluate a new dental management protocol before hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38 (3):237–42.

Publication Dates

  • Publication in this collection
    09 Oct 2023
  • Date of issue
    Jul-Sep 2023

History

  • Received
    23 Mar 2023
  • Accepted
    17 Apr 2023
  • Published
    30 May 2023
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) R. Dr. Diogo de Faria, 775 cj 133, 04037-002, São Paulo / SP - Brasil - São Paulo - SP - Brazil
E-mail: htct@abhh.org.br